James Bochnowski Biography and Net Worth

Director of Jaguar Health


Mr. Bochnowski has served as a member of our board of directors since February 2014 and as Chairman of our board since June 2014. Since 1988, Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1993, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology.

We believe Mr. Bochnowski is qualified to serve on our board of directors due to his significant experience with venture capital backed healthcare companies and experience as both an executive officer and member of the board of directors of numerous companies.

What is James J. Bochnowski's net worth?

The estimated net worth of James J. Bochnowski is at least $85,813.33 as of June 3rd, 2021. Mr. Bochnowski owns 954,542 shares of Jaguar Health stock worth more than $85,813 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Bochnowski may own. Learn More about James J. Bochnowski's net worth.

How do I contact James J. Bochnowski?

The corporate mailing address for Mr. Bochnowski and other Jaguar Health executives is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. Jaguar Health can also be reached via phone at (415) 371-8300. Learn More on James J. Bochnowski's contact information.

Has James J. Bochnowski been buying or selling shares of Jaguar Health?

James J. Bochnowski has not been actively trading shares of Jaguar Health during the last quarter. Most recently, James J. Bochnowski sold 292 shares of the business's stock in a transaction on Thursday, June 3rd. The shares were sold at an average price of $1.75, for a transaction totalling $511.00. Following the completion of the sale, the director now directly owns 954,542 shares of the company's stock, valued at $1,670,448.50. Learn More on James J. Bochnowski's trading history.

James J. Bochnowski Insider Trading History at Jaguar Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2021Sell292$1.75$511.00954,542View SEC Filing Icon  
7/23/2019Buy180,582$2.00$361,164.00View SEC Filing Icon  
2/8/2016Buy160,000$2.50$400,000.00View SEC Filing Icon  
See Full Table

James J. Bochnowski Buying and Selling Activity at Jaguar Health

This chart shows James J Bochnowski's buying and selling at Jaguar Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jaguar Health Company Overview

Jaguar Health logo
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $0.09
Low: $0.07
High: $0.09

50 Day Range

MA: $0.08
Low: $0.06
High: $0.14

2 Week Range

Now: $0.09
Low: $0.05
High: $1.22

Volume

58,655,581 shs

Average Volume

38,870,617 shs

Market Capitalization

$4.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31